" class="no-js "lang="en-US"> Northwest Biotherapeutics Announces $15 Million Financing - Medtech Alert
Wednesday, February 08, 2023

Breaking News

Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, a Rare Life-threatening Blood Condition Ultima Genomics and Integrated DNA Technologies to Enable Application Portfolio on Ultima Sequencing Platforms Radiology Imaging Associates Launches the Enhanced Breast Cancer Detection Program
Northwest Biotherapeutics Announces $15 Million Financing | Pharmtech Focus

November 30 2021

Northwest Biotherapeutics Announces $15 Million Financing

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company’s cash reserves above $20 million.

The Company plans to use the funding to help accelerate its activities related to its brain cancer program.  The financing is in the form of a 22-month loan which requires no payments for 8 months, and then provides for a subsequent 14-month amortization period. The loan has a provision for prepayment, an annualized interest rate of 8% and OID of 10%.  Upon announcement of the top line data (“TLD”) from the Company’s Phase III clinical trial of DCVax®-L for Glioblastoma brain cancer, the lender will have a then-springing right to exchange the outstanding balance of the loan for common shares priced at the price of the first private placement transaction following TLD less a 12% discount, and to purchase another 50% of that number of shares at the same price.  This then-springing right expires 14 days after that post-TLD private placement. 

Companies In This Post

Northwest Biotherapeutics | Pharmtech Focus

Northwest Biotherapeutics
  1. Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer

    Appointments

     Read more
  2. Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.

    News

     Read more
  3. Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth

    Fundraising

     Read more
  4. Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer

    Appointments

     Read more
  5. TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials

    Fundraising

     Read more
More On